Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

被引:8
|
作者
Ma, Xiaohong [1 ,2 ]
Ma, Rong [3 ]
Zhang, Mengzhe [3 ]
Qian, Baicheng [1 ]
Wang, Baoliang [1 ]
Yang, Weijing [3 ]
机构
[1] Henan Univ Chinese Med, Affiliated Hosp 1, Dept Neurosci, Zhengzhou 450000, Peoples R China
[2] Henan Univ Chinese Med, Clin Med Sch 1, Zhengzhou 450046, Peoples R China
[3] Zhengzhou Univ, Sch Pharmaceut Sci, Henan Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
multiple sclerosis; immunotherapy; T cells; B cells; innate immune cells; REGULATORY T-CELLS; PLACEBO-CONTROLLED TRIAL; MYELIN BASIC-PROTEIN; GLATIRAMER ACETATE; B-CELLS; DENDRITIC CELLS; DOUBLE-BLIND; IFN-BETA; MENINGEAL INFLAMMATION; NEUROMYELITIS-OPTICA;
D O I
10.3390/pharmaceutics15030728
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the central nervous system. The main pathological features are inflammatory reaction, demyelination, axonal disintegration, reactive gliosis, etc. The etiology and pathogenesis of the disease have not been clarified. The initial studies believed that T cell-mediated cellular immunity is the key to the pathogenesis of MS. In recent years, more and more evidence has shown that B cells and their mediated humoral immune and innate immune cells (such as microglia, dendritic cells, macrophages, etc.) also play an important role in the pathogenesis of MS. This article mainly reviews the research progress of MS by targeting different immune cells and analyzes the action pathways of drugs. The types and mechanisms of immune cells related to the pathogenesis are introduced in detail, and the mechanisms of drugs targeting different immune cells are discussed in depth. This article aims to clarify the pathogenesis and immunotherapy pathway of MS, hoping to find new targets and strategies for the development of therapeutic drugs for MS.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Recent progress in the diagnosis and treatment of multiple sclerosis
    Pender, MP
    JOURNAL OF CLINICAL NEUROSCIENCE, 1999, 6 (05) : 367 - 372
  • [2] Dendritic cells in the CNS: immune regulators and therapeutic targets for multiple sclerosis treatment
    Zozulya, Alla L.
    Reinke, Emily K.
    Ling, Changying
    Sandor, Matyas
    Fabry, Zsuzsanna
    FUTURE NEUROLOGY, 2007, 2 (01) : 97 - 106
  • [3] Progress in Recent Research on Multiple Sclerosis
    Davison, Alan N.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1978, 6 : 443 - 447
  • [4] Progress in the treatment of multiple sclerosis
    Chan, Andrew
    Kamber, Nicole
    Hoepner, Robert
    Salmen, Anke
    THERAPEUTISCHE UMSCHAU, 2018, 75 (07) : 405 - 409
  • [5] New targets for treatment of multiple sclerosis
    Steinman, Lawrence
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2008, 274 (1-2) : 1 - 4
  • [6] PI3K-gamma: Developing immune targets for the treatment of multiple sclerosis
    Smith, Kristen
    Gatson, Na Tosha
    Williams, Jessica
    Kithcart, Aaron
    Mavrikis, Gina
    Song Fei
    Satoskar, Abhay
    Whitacre, Caroline C.
    JOURNAL OF NEUROIMMUNOLOGY, 2008, 203 (02) : 239 - 240
  • [7] Mesenchymal stem cells for multiple sclerosis: effect of treatment on peripheral immune cells
    Schiavetti, I.
    Freedman, M. S.
    Martino, G.
    Palmeri, S.
    Ivaldi, F.
    Calo, I.
    Sormani, M. P.
    Uccelli, A.
    Laroni, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 624 - 625
  • [8] Recent developments in multiple sclerosis treatment
    Mirowska-Guzel, Dagmara
    PHARMACOLOGICAL REPORTS, 2010, 62 : 26 - 26
  • [9] Recent developments in multiple sclerosis treatment
    Dagmara Mirowska-Guzel
    Pharmacological Reports, 2010, 62 : 26 - 26
  • [10] Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
    Gross, Catharina C.
    Ahmetspahic, Diana
    Ruck, Tobias
    Schulte-Mecklenbeck, Andreas
    Schwarte, Kathrin
    Jorgens, Silke
    Scheu, Stefanie
    Windhagen, Susanne
    Graefe, Bettina
    Melzer, Nico
    Klotz, Luisa
    Arolt, Volker
    Wiendl, Heinz
    Meuth, Sven G.
    Alferink, Judith
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (06):